Akari Therapeutics (AKTX) Other Non-Current Liabilities (2014 - 2026)
Akari Therapeutics (AKTX) posted quarterly Other Non-Current Liabilities of $17000.0 for Q1 2026, down 93.61% year-on-year from $266000.0 in Q1 2025, and down 92.61% on a QoQ basis from $230000.0 in Q4 2025.
Akari Therapeutics (AKTX) Other Non-Current Liabilities (2014 - 2026) Analysis & Trends
Akari Therapeutics (AKTX) has reported Other Non-Current Liabilities for 7 consecutive years, with $17000.0 the latest figure, recorded in Q1 2026.
- Quarterly Other Non-Current Liabilities fell 93.61% year-over-year to $17000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17000.0 (down 93.61% YoY) and the FY2025 annual result came in at $230000.0, down 39.95% from the prior year.
- Other Non-Current Liabilities fell to $17000.0 in Q1 2026 per AKTX's latest filing, from $230000.0 in the prior quarter.
- Over the last five years, Other Non-Current Liabilities for AKTX reached as high as $7.9 million in Q4 2022 and fell as low as $17000.0 in Q1 2026.
- A 5-year average of $1.0 million and a median of $179000.0 in 2025 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2024 — Other Non-Current Liabilities sank 94.13% — and 2025, when it jumped 166.0%.
- Year by year, Other Non-Current Liabilities stood at $7.9 million in 2022, then sank by 84.04% to $1.3 million in 2023, then sank by 69.43% to $383000.0 in 2024, then tumbled by 39.95% to $230000.0 in 2025, then slumped by 92.61% to $17000.0 in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $17000.0, $230000.0, and $100000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Akari Therapeutics | 86.55 Mn | 86.55 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17,000.00 |
| Dec 31, 2025 | 230,000.00 |
| Sep 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 128,000.00 |
| Mar 31, 2025 | 266,000.00 |
| Dec 31, 2024 | 383,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Mar 31, 2024 | 100,000.00 |
| Dec 31, 2023 | 1.25 Mn |
| Jun 30, 2023 | 1.70 Mn |
| Dec 31, 2022 | 7.85 Mn |
| Sep 30, 2015 | 26.00 Mn |
| Jun 30, 2015 | 43,000.00 |
| Mar 31, 2015 | 38,000.00 |
| Dec 31, 2014 | 33,000.00 |